Afatinib, trametinib and regorafenib are three costly oral oncology drugs with a short shelf-life after the original container has been opened. Their short shelf-lives are due to degradation on exposure to moisture. Therefore, manufacturers recommend them to be dispensed in the original packaging with the desiccant. However, the prescribed quantities do not always match the quantities in the original packaging, usually because of dose modifications for toxicities. This leads to potentially significant drug wastage and financial losses. We describe some potential approaches to this issue.
Novartis Pharmaceuticals Canada Inc. MEKINIST® product monograph. Dorval, Quebec, 15 May 2017.
5.
Pan-Canadian Oncology Drug Review; pCODR Expert Review Committee. Final Recommendation. Regorafenib. Treatment of patients with metastatic colorectal cancer (CRC), and an ECOG status of ≤1, who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy, www.cadth.ca/pcodr/find-a-review (2015, accessed 27 October 2017).
6.
Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee. Final Recommendation. Trametinib. For use as a monotherapy for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, www.cadth.ca/pcodr/find-a-review (2013, accessed 27 October 2017).
7.
Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee. Final Recommendation. Afatinib. For the first line treatment of EGFR mutation positive, advanced non-small cell lung cancer patients, www.cadth.ca/pcodr/find-a-review (2014, accessed 27 October 2017).
8.
FlahertyKTRobertCHerseyPet al.Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med2012; 367: 107–114.
9.
LongGVStroyakovskiyDGogasHet al.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med2014; 371: 1877–1888.
10.
WuYLZhouCHuCPet al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol2014; 15: 213–222.
11.
MillerVAHirshVCadranelJet al.Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefi tinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol2012; 13: 528–538.
12.
SoriaJCFelipECoboMet al.Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol2015; 16: 897–907.
13.
DemetriGDet al.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet2013; 381: 295–302.
14.
GrotheyAVan CutsemESobreroAet al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet2013; 381: 303–312.
15.
Skrabs S, Funke A, Kresse M, et al., inventors; Bayer Healthcare LLC, assignee. Coated pharmaceutical composition containing regorafenib. US patent 2014/0065212 A1. 6 March 2014.
16.
Health Professions Act Bylaws. Schedule F, part 2, Hospital Pharmacy Standards of Practice. Drug repackaging and compounding, www.bcpharmacists.org/acts-and-bylaws (accessed 27 October 2017).
